Log in

Icon Stock Forecast, Price & News

-3.42 (-1.89 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $177.17
50-Day Range
MA: $185.64
52-Week Range
Now: $177.17
Volume285,236 shs
Average Volume263,869 shs
Market Capitalization$9.50 billion
P/E Ratio29.53
Dividend YieldN/A
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Read More
Icon logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:ICLR



Sales & Book Value

Annual Sales$2.81 billion
Cash Flow$8.34 per share
Book Value$30.91 per share


Net Income$373.99 million


Market Cap$9.50 billion
Next Earnings Date10/28/2020 (Estimated)
-3.42 (-1.89 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Icon (NASDAQ:ICLR) Frequently Asked Questions

How has Icon's stock price been impacted by COVID-19 (Coronavirus)?

Icon's stock was trading at $152.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ICLR stock has increased by 16.1% and is now trading at $177.17.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Icon?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Icon

When is Icon's next earnings date?

Icon is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Icon

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) announced its quarterly earnings results on Wednesday, July, 22nd. The medical research company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.10. The medical research company had revenue of $620.23 million for the quarter, compared to analysts' expectations of $594.31 million. Icon had a return on equity of 22.21% and a net margin of 12.03%.
View Icon's earnings history

What guidance has Icon issued on next quarter's earnings?

Icon issued an update on its FY20 earnings guidance on Wednesday, July, 22nd. The company provided EPS guidance of $6.00-6.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.87. The company issued revenue guidance of $2.65-2.75 billion, compared to the consensus revenue estimate of $2.68 billion.

What price target have analysts set for ICLR?

12 brokers have issued 12 month price targets for Icon's shares. Their forecasts range from $140.00 to $220.00. On average, they anticipate Icon's stock price to reach $177.20 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price.
View analysts' price targets for Icon

Are investors shorting Icon?

Icon saw a drop in short interest in August. As of August 14th, there was short interest totaling 507,600 shares, a drop of 13.4% from the July 30th total of 586,300 shares. Based on an average daily volume of 228,800 shares, the days-to-cover ratio is presently 2.2 days. Currently, 1.0% of the company's stock are short sold.
View Icon's Short Interest

Who are some of Icon's key competitors?

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), CVS Health (CVS), NVIDIA (NVDA), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).

Who are Icon's key executives?

Icon's management team includes the following people:
  • Dr. Steven A. Cutler, CEO & Director (Age 59)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 40)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

Who are Icon's major shareholders?

Icon's stock is owned by a number of retail and institutional investors. Top institutional shareholders include WCM Investment Management LLC (7.24%), Pendal Group Ltd (3.75%), Comgest Global Investors S.A.S. (3.54%), Wasatch Advisors Inc. (2.96%), Ninety One UK Ltd (2.06%) and Principal Financial Group Inc. (1.81%).

Which institutional investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, CIBC Private Wealth Group LLC, Clark Capital Management Group Inc., Wasatch Advisors Inc., Sei Investments Co., Bank of America Corp DE, Bamco Inc. NY, and Globeflex Capital L P.

Which institutional investors are buying Icon stock?

ICLR stock was purchased by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Ninety One UK Ltd, Nordea Investment Management AB, Marshall Wace North America L.P., Applied Research Investments LLC, WCM Investment Management LLC, FIL Ltd, and William Blair Investment Management LLC.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $177.17.

How big of a company is Icon?

Icon has a market capitalization of $9.50 billion and generates $2.81 billion in revenue each year. The medical research company earns $373.99 million in net income (profit) each year or $6.88 on an earnings per share basis. Icon employs 14,650 workers across the globe.

What is Icon's official website?

The official website for Icon is www.iconplc.com.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.